Irinotecan and Cisplatin Combination Chemotherapy Plus Concurrent Thoracic Irradiation for Patients with Limited Disease Small Cell Lung Cancer
Journal of Lung Cancer
; : 49-55, 2011.
Article
en En
| WPRIM
| ID: wpr-210440
Biblioteca responsable:
WPRO
ABSTRACT
PURPOSE:
To evaluate the antitumor activity and safety of irinotecan plus cisplatin combination chemotherapy with concurrent thoracic radiotherapy (TRT) in patients with limited disease (LD) small cell lung cancer (SCLC). MATERIALS ANDMETHODS:
Patients with pathologically-confirmed LD SCLC with the following inclusion criteria were retrospectively analyzed age > or =18 years; measurable lesion; Eastern Cooperative Oncology Group Performance Status 0~2; chemotherapy naive; and adequate bone marrow and organ function. Patients received an intravenous (IV) infusion of irinotecan (35 mg/m2 on days 1, 8, and 15) and cisplatin (60 mg/m2 on day 1), which was repeated every 4 weeks for up to 6 cycles. Concurrent TRT was administered with the beginning of chemotherapy. Irinotecan was increased to 60 mg/m2 after completion of TRT. Patients with a complete response (CR) subsequently received prophylactic cranial irradiation.RESULTS:
Nineteen patients were analyzed. There were 8 patients (42.1%) with CR, 9 patients (47.4%) with partial response, and 1 patient each (5.3%) with stable disease and progressive disease (PD). The overall response rate was 89.5%. The median progression-free survival was 7.6 months (95% confidence interval [CI], 1.3~14.0 months) and the median overall survival was 12.4 months (95% CI, 0.5~24.2 months). The 2-year survival rate of the CR patients was 75.0%. No grade 4 hematologic toxicity was reported. Frequently reported toxicities were nausea (10 patients), radiation-induced pneumonitis (10 patients), and neutropenia (6 patients). Radiation-related severe toxicities were frequently reported. Three patients had treatment-related deaths.CONCLUSION:
This study supports the activity and tolerability of irinotecan plus cisplatin with concurrent TRT in patients with LD SCLC.Palabras clave
Texto completo:
1
Base de datos:
WPRIM
Asunto principal:
Neumonía
/
Médula Ósea
/
Camptotecina
/
Tasa de Supervivencia
/
Estudios Retrospectivos
/
Cisplatino
/
Supervivencia sin Enfermedad
/
Quimioterapia Combinada
/
Carcinoma Pulmonar de Células Pequeñas
/
Náusea
Tipo de estudio:
Observational_studies
Límite:
Humans
Idioma:
En
Revista:
Journal of Lung Cancer
Año:
2011
Tipo del documento:
Article